Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
CAPSULE, LIQUID FILLED
**4.2. Posology and Method of Administration** _Adult males (including elderly):_ _AVODART_ can be administered alone or in combination with the alpha-blocker tamsulosin (0.4 mg). The recommended dose of _AVODART_ is one capsule (0.5 mg) taken orally once a day. The capsules should be swallowed whole and not chewed or opened, as contact with the capsule contents may result in irritation of the oropharyngeal mucosa. _AVODART_ may be taken with or without food. Although an improvement may be observed at an early stage, it can take up to 6 months before a response to the treatment can be achieved. No dose adjustment is necessary in the elderly. _Renal impairment_ The effect of renal impairment on dutasteride pharmacokinetics has not been studied. No adjustment in dosage is anticipated for patients with renal impairment (see 5.2 Pharmacokinetic Properties – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). _Hepatic impairment_ The effect of hepatic impairment on dutasteride pharmacokinetics has not been studied so caution should be used in patients with mild to moderate hepatic impairment (see 4.4 Special Warnings and Special Precautions for Use and 5.2 Pharmacokinetic Properties – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). In patients with severe hepatic impairment, the use of dutasteride is contraindicated (See section 4.3 Contraindications).
ORAL
Medical Information
**4.1. Therapeutic Indications** _AVODART_ is indicated for the treatment and control of benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce prostate size, reduce the risk of acute urinary retention, and reduce the need for BPH-related surgery. In addition, _AVODART_ in combination with the alpha-blocker tamsulosin is indicated for the treatment of symptomatic BPH in men with an enlarged prostate.
**4.3. Contraindications** _AVODART_ is contraindicated for use in women, children and adolescents (see 4.6 Pregnancy and Lactation – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). _AVODART_ is contraindicated in patients with hypersensitivity to dutasteride, other 5-alpha- reductase inhibitors, or any of the excipients. _AVODART_ is contraindicated in patients with severe hepatic impairment.
G04CB02
dutasteride
Manufacturer Information
GLAXOSMITHKLINE PTE LTD
Catalent France Beinheim S.A.
Delpharm Poznań S.A.
Active Ingredients
Documents
Package Inserts
Avodart_PI.pdf
Approved: February 28, 2023